CanSino Biologics Inc. announced that, as proposed by the National Health Commission of the People's Republic of China and approved by the National Medical Products Administration of the PRC upon demonstration, the Company ' s Recombinant COVID-19 Vaccine for Inhalation has been included for emergency use as a booster vaccine in the PRC. Further purchases by relevant national authorities, if any, will have certain positive effects on the results of the Company. Ad5-nCoV for Inhalation is a genetic engineered inhaled vaccine to prevent COVID-19 disease, which can not only stimulate humoral and cellular immunity, but also induce mucosal immunity to achieve triple comprehensive protection efficiently without intramuscular injection.

Ad5-nCoV for Inhalation has unique advantages of safety, effectiveness, painlessness, convenience and availability. As announced by the Company on March 23, 2021, the clinical trial application for the Ad5-nCoV for Inhalation has been approved by the NMPA.